v3.26.3
Revenue -Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Deferred revenue      
Deferred revenue, beginning balance $ 498,996 $ 1,121,886  
Additions 39,257 25,595  
Deductions (106,041) (646,125)  
Deferred revenue, ending balance 432,212 501,356  
Revenue Recognition      
Deferred revenue 102,201   $ 140,053
Sanofi Transition Services      
Revenue Recognition      
Deferred revenue 74,900    
Other partners      
Revenue Recognition      
Deferred revenue 21,400    
Nuvaxovid      
Revenue Recognition      
Deferred revenue $ 9,600    
Canada Advanced Purchase Agreement      
Revenue Recognition      
Deferred revenue   $ 555,700